Abstract | BACKGROUND:
Chemotherapy regimens have improved prognosis and mortality of patients with malignant diseases. The development of therapies, however, has widened the cardiotoxic spectrum and the cardiacrelated effects of antineoplastic drugs. METHODS: RESULTS: CONCLUSION: Since the number of long-term survivors following the diagnosis and treatment of malignant disease will continue to increase, cardio-oncology will continue to evolve. Therefore, a better understanding of potential cardiovascular effects of chemotherapeutic regiments and the earlier identification and treatment of high-risk patients would be the focus of research in the future.
|
Authors | Evangelos Oikonomou, Μaria Anastasiou, Gerasimos Siasos, Emmanuel Androulakis, Amanda Psyrri, Konstantinos Toutouzas, Dimitris Tousoulis |
Journal | Current pharmaceutical design
(Curr Pharm Des)
Vol. 24
Issue 37
Pg. 4424-4435
( 2018)
ISSN: 1873-4286 [Electronic] United Arab Emirates |
PMID | 30636595
(Publication Type: Journal Article, Review)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Antineoplastic Agents
- Doxorubicin
|
Topics |
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cardiotoxicity
- Cardiovascular Diseases
(diagnosis, drug therapy, physiopathology)
- Doxorubicin
(adverse effects, therapeutic use)
- Humans
- Neoplasms
(diagnosis, drug therapy, physiopathology)
|